Welcome to our dedicated page for Lyell Immunopharma news (Ticker: LYEL), a resource for investors and traders seeking the latest updates and insights on Lyell Immunopharma stock.
Lyell Immunopharma, Inc. (Nasdaq: LYEL) is a late-stage clinical company developing next-generation CAR T-cell therapies for cancer, and its news flow reflects the progress of these programs. Company announcements highlight clinical data from trials of rondecabtagene autoleucel (ronde‑cel, also referred to as LYL314) in relapsed and/or refractory large B-cell lymphoma (LBCL), including reported overall response rates, complete response rates, durability of responses, and safety findings from Phase 1/2 and pivotal studies.
News updates frequently cover milestones in Lyell’s pivotal development of ronde‑cel, such as the initiation and conduct of the single‑arm PiNACLE trial in the third‑ or later‑line setting and the Phase 3 PiNACLE – H2H head‑to‑head trial in the second‑line setting against approved CD19 CAR T-cell therapies. These releases often include details on trial design, patient populations, endpoints, and presentations at major scientific meetings like the American Society of Hematology (ASH) and the International Conference on Malignant Lymphoma.
For solid tumors, Lyell’s news also reports on LYL273, a GCC‑targeted CAR T-cell product candidate in Phase 1 development for refractory metastatic colorectal cancer. Disclosures include response rates, disease control rates, safety observations, and regulatory designations such as Fast Track status from the U.S. FDA. Additional corporate news items describe licensing transactions, equity financings, and operational updates that support the advancement of Lyell’s pipeline and manufacturing capabilities.
Investors and observers following LYEL news can use this page to review company-issued press releases on clinical trial readouts, regulatory designations, scientific conference presentations, licensing agreements, and capital raises related to Lyell’s CAR T-cell programs in hematologic malignancies and solid tumors.
Lyell Immunopharma (Nasdaq: LYEL), a clinical-stage T-cell reprogramming company, has announced its participation in two upcoming investor conferences in September 2024. The company's senior management team will present at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 4th at 10:45 am ET and the H.C. Wainwright 26th Annual Global Investment Conference on September 9th at 8:30 am ET.
Lyell Immunopharma specializes in developing cell therapies for patients with solid tumors or hematologic malignancies. Interested parties can access live webcasts of the presentations through the Investors section of Lyell's website. Replays will be available on the company's website following each presentation.
Lyell Immunopharma (NASDAQ: LYEL) reported Q2 2024 results and business highlights:
- LYL797 Phase 1 trial showed 40% objective response rate and 60% clinical benefit rate in triple-negative breast cancer at highest dose
- Expanded LYL797 development into four new tumor types
- FDA cleared IND for LYL119, a next-gen ROR1-targeted CAR T-cell therapy
- $491.1 million in cash and equivalents as of June 30, 2024
- Net loss of $45.8 million for Q2 2024, compared to $63.9 million in Q2 2023
- R&D expenses decreased to $40.3 million from $47.5 million year-over-year
- G&A expenses decreased to $12.3 million from $19.0 million year-over-year
- Cash runway extended into 2027
Lyell Immunopharma has announced initial clinical data from its Phase 1 trial of LYL797, a ROR1-targeted CAR-T cell product enhanced with anti-exhaustion technology. Key findings include a 40% objective response rate (ORR) and a 60% clinical benefit rate (CBR) at the highest dose of 150 million CAR T cells in patients with triple-negative breast cancer (TNBC). The trial demonstrated that LYL797 can proliferate, infiltrate tumors, and kill cancer cells. No dose-limiting toxicities were reported in patients without lung metastases, although treatable pneumonitis was observed in those with lung involvement. Lyell is expanding the trial to include other ROR1+ cancers and has submitted an IND for LYL119, their next-generation product. An investor webcast will be held today at 8:30 am ET.
Lyell Immunopharma, a clinical-stage company specializing in T-cell reprogramming for solid tumor cell therapies, announced participation in the Goldman Sachs 45th Annual Global Healthcare Conference. The event is scheduled for June 10 at 4:00 pm ET. Senior management will present during this conference, and a live webcast will be accessible through Lyell's investor section on www.lyell.com. A replay will also be made available post-presentation.
Lyell Immunopharma, a clinical-stage T-cell reprogramming company, will participate in the BofA Securities Health Care Conference on May 14, 2024. The company will showcase its diverse pipeline of cell therapies for solid tumors. Investors can access the live webcast on the Company's website.
Lyell Immunopharma, Inc. (Nasdaq: LYEL) reported business highlights for Q1 2024, including strong financial position with $526.3 million in cash and ongoing advancement of diverse cell therapy pipeline. Key updates include initial clinical data expected for LYL797 and LYL845, IND submission for LYL119, and promising nonclinical data presented at AACR Annual Meeting 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.